Related references
Note: Only part of the references are listed.Quantitative accuracy of 177Lu SPECT reconstruction using different compensation methods: phantom and patient studies
Eero Hippelainen et al.
EJNMMI RESEARCH (2016)
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Eva Tiensuu Janson et al.
ACTA ONCOLOGICA (2014)
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
Giovanni Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing Lu-177-DOTA-Octreotate Treatment
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy
Ulrike Garske et al.
ACTA ONCOLOGICA (2012)
Lutetium-labelled peptides for therapy of neuroendocrine tumours
B. L. R. Kam et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma
Ulrike Garske et al.
THERANOSTICS (2012)
Estimation of absorbed dose to the kidneys in patients after treatment with Lu-177-octreotate: comparison between methods based on planar scintigraphy
Maria Larsson et al.
EJNMMI RESEARCH (2012)
177Lu-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
Michael Garkavij et al.
CANCER (2010)
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Dik J. Kwekkeboom et al.
ENDOCRINE-RELATED CANCER (2010)
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Mattias Sandstrom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
Erik Vegt et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Results of individual patient dosimetry in peptide receptor radionuclide therapy with Lu-177 DOTA-TATE and Lu-177 DOTA-NOC
Christiane Wehrmann et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Radiation protection in radionuclide therapies with 90Y-conjugates:: risks and safety
Marta Cremonesi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Share Paper
